Genome in Biological Technology

Human Genome Sciences Announces Closing of Public Offering

ROCKVILLE, Md., Aug. 3 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced the closing of its public offering of 26,697,250 newly issued shares of its common stock at a price to the public of $14.00 per share, which includes 3,482,250 shares sold upon exerc...

Human Genome Sciences Announces Pricing of Public Offering of Common Stock

ROCKVILLE, Md., July 28 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced the pricing of its underwritten public offering of 23,215,000 newly issued shares of its common stock at a price to the public of $14.00 per share. The size of the offering was inc...

Human Genome Sciences Announces Proposed Public Offering of Common Stock

ROCKVILLE, Md., July 27 /PRNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced that it has commenced an underwritten public offering of up to 18,000,000 shares of its common stock. The Company intends to grant the underwriters a 30-day option to purchase up to an add...

Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government

ROCKVILLE, Md., July 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced that the U.S. Government has exercised its option to purchase an additional 45,000 doses of raxibacumab (ABthrax(TM)) for the Strategic National Stockpile, to be delivered...

Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus

ROCKVILLE, Maryland, July 1 /PRNewswire-USNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced that it expects to have top-line results available on Monday, July 20, from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly LymphoSta...

febit First to Offer Newly Published Mouse Genome on a Chip for DNA/RNA Detection and Enrichment

febit Technology Enables the Conversion of New Sequence Data into Biochips for Gene Expression Profiling and Sequence Capture for Next-Generation Sequencing Within Days LEXINGTON, Mass. and HEIDELBERG, Germany, June 29 /PRNewswire/ -- febit holding gmbh announced today the launch of the f...

Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray Conference

ROCKVILLE, Md., June 19 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) announced today that its presentation at the 2009 Piper Jaffray Europe Conference will be webcast and may be accessed at www.hgsi.com . (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGS...

Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)

- Trial conducted by Novartis evaluating safety and efficacy of Albuferon administered every four weeks in combination with ribavirin in patients with genotypes 2 and 3 hepatitis C - ROCKVILLE, Md., June 19 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announce...

Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus

- Phase 2 continuation data demonstrated sustained improvement in disease activity and patient response rate through four years of BENLYSTA therapy - - Frequency of disease flares as measured by the SELENA SLEDAI flare index and by BILAG A or B organ domain scores decreased over four years o...

MEDomics Announces MitoDx(TM), the First NextGen Mitochondrial Genome Diagnostic Test

Highly Sensitive Genetic Test Provides Early Diagnosis of Mitochondrial Diseases LOS ANGELES, June 9 /PRNewswire/ -- MEDomics, LLC ( www.medomics.com ) announces an innovative test for early diagnosis of mitochondrial diseases, a group of disorders that can result in neurological dysfunctio...

Kornberg Associates Architects Selected to Design Research Areas of Malaysia Genome Institute

MENLO PARK, Calif., June 3 /PRNewswire/ -- Kornberg Associates | Architects ( www.kornberg.com ) has been selected to design the research areas of the new Malaysia Genome Institute. Ken Kornberg, president and founder, made the announcement. The Malaysia Genome Institute (GENOMalaysia; h...

New and Expanded Free Tutorials on UCSC Genome Browser Now Available

University of California, Santa Cruz and OpenHelix announce the free availability of online free tutorial suites on the UCSC Genome Browser. (PRWEB) June 3, 2009 -- University of California, Santa Cruz and OpenHelix today announced the free availability of tutorial suit...

Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement

ROCKVILLE, Md. and NOTTINGHAM, UK, May 7 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) and Novozymes Biopharma, a part of Novozymes (Nasdaq: NZYM B), today announced that they have amended an existing license agreement to allow both companies to expand application of thei...

Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments

- First HGS product sales achieved with delivery of ABthrax(TM) to U.S. Strategic National Stockpile - - $177 million in first quarter revenues; cash balance of $397 million as of March 31, up $24 million from year-end 2008 - - Positive results for second Phase 3 trial of Albuferon (R...

Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize

Breakthrough technology could transform agricultural advancement Indianapolis (PRWEB) April 29, 2009 - Scientists at Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE:DOW), have demonstrated insertion of a gene for a herbicide-tolerant tr...

New cow genome sequence released

Scientists from the University of Maryland have published their assembly of the domestic cow ( Bos taurus ), an important new resource for the genetics community. The new version of the cow genome improves considerably on other assemblies, in terms of both completeness and accuracy. The article de...

International science consortium publishes analysis of domestic cattle genome sequence

The U.S. Department of Agriculture and the National Institutes of Health announced today that an international consortium of researchers has published the genome of domestic cattle, the first livestock mammal to have its genetic blueprint sequenced and analyzed. The landmark research will bolster ...

Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2009 Financial Results

ROCKVILLE, Md., April 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended March 31, 2009. These results are expected to be disclosed on Wednesday, April 29, 2009, a...

Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference

ROCKVILLE, Md., March 27 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) announced today that its presentation at the 4th Annual Citi Biotech Day will be webcast and may be accessed at www.hgsi.com . (Logo: http://www.newscom.com/cgi-bin/prnh/200...

Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology

ROCKVILLE, Md. and EXTON, Pa., March 25 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) and Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic...

Human Genome Sciences to Sponsor Conference Call

ROCKVILLE, Md., March 9 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced that it will sponsor a conference call to discuss the results of its ACHIEVE 1 Phase 3 trial of Albuferon(R) (albinterferon alfa-2b) in patients with genotype 1 chronic hepatiti...

Sigma-Aldrich Introduces MISSION(R) LentiPlex(TM) Pooled shRNA Libraries to Enable Rapid Whole Genome Screening in Primary Cells, Stem Cells or Tumor Cells

ST. LOUIS, March 3 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL ) today announced the global release of the MISSION(R) LentiPlex(TM) Pooled Human and Murine shRNA Libraries ( http://www.sigma-aldrich.com/lentiplex ). Using the shRNA collections of The RNAi Consortium (TRC), the ...

BioNanomatrix's Revolutionary Whole Genome Analysis Platform Named to MIT Technology Review's Annual 10 Emerging Technologies List

-Company's Goal Is to Lower the Cost of Genome Analysis to $100 In Order To Make Genomic Information Universally Available for Routine Medical Care- PHILADELPHIA, Feb. 24 /PRNewswire/ -- BioNanomatrix, Inc., a developer of breakthrough whole genome imaging and analysis platforms for biomedica...

Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results

ROCKVILLE, Md., Feb. 19 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced that it will sponsor a conference call to discuss its financial results for the year ended December 31, 2008. These results are expected to be disclosed on Thursday, February 26, 2009, ...

Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes

ROCKVILLE, Md., Feb. 17 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced that GlaxoSmithKline (NYSE: GSK ) has initiated a Phase 3 clinical trial program to evaluate the efficacy, safety and tolerability of Syncria (R) (albiglutide) in the long-term treatm...

Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting

MOUNTAIN VIEW, Calif., Jan. 30 /PRNewswire/ -- Complete Genomics Inc., a newly launched, third-generation human genome sequencing company, today announced that it will release its sequencing data publically for the first time at the 10th annual Advances in Genome Biology and Technology ...

Canada's Genome Centres Promote Collaboration at International Conference

SAN DIEGO, Jan. 19 /PRNewswire/ - Canada's six genome centres demonstrated the power of partnerships by hosting their 2nd Annual Canadian Genomics Reception at the International Plant and Animal Genomics Conference in San Diego last week. More than 150 researchers, funders and other international ...

Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C

- Trial conducted by Novartis to evaluate safety and efficacy of Albuferon administered every four weeks in combination with ribavirin in patients with genotypes 2 and 3 hepatitis C - ROCKVILLE, Md., Jan. 12 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announc...

Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference

ROCKVILLE, Md., Jan. 9 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) announced today that its presentation at the 27th Annual JPMorgan Healthcare Conference will be webcast and may be accessed at www.hgsi.com (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HG...

deCODE to Integrate New Genetic Risk Factor for Type 2 Diabetes Into Its deCODEme(TM) Personal Genome Scan Service

REYKJAVIK, Iceland, Dec. 8 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN ) today announced the discovery by an international consortium of scientists from deCODE and major European and US academic institutions of a single letter variation in the human genome (SNP) that is associated wi...

Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C

- Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to Pegasys (peginterferon alfa-2a) in the ACHIEVE 2/3 trial in patients with genotypes 2 and 3 chronic hepatitis C - - Patients receiving 900-mcg Albuferon had comparable rates of serious adverse events, seve...

J. Craig Venter Institute Researchers Publish Significant Advance in Genome Assembly Technology

Advance Allows for More Efficient Construction of Synthetic Genomes ROCKVILLE, Md., Dec. 4 /PRNewswire-USNewswire/ -- Researchers at the J. Craig Venter Institute (JCVI), a not-for-profit genomic research organization, have published a paper describing a significant advance in genome ass...

ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies

PARIS, November 28 /PRNewswire-FirstCall/ -- ExonHit Therapeutics S.A. (Alternext: ALEHT), a drug and diagnostic discovery company, announces today the availability of its new SpliceArray(TM) for use in studying mouse models of human disease. These SpliceArray(TM) products help our clients acceler...

Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation

OMAHA, Neb., Nov. 20 /PRNewswire-FirstCall/ -- Transgenomic (OTC Bulletin Board: TBIO) today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) award by the National Science Foundation (NSF) to support the development of its proposed SURVEYOR Endonuclease Adapto...

A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks

BOSTON, Nov. 12 /PRNewswire/ -- WHO and CDC have stated that the predictive accuracy of their annual formulations for human influenza vaccines is "suboptimal" -- often correct less than 50% of the time, especially for seniors. Perhaps in part because we are not yet accurate in our predictions ...

Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference

ROCKVILLE, Md., Nov. 7 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) announced today that its presentation at the Deutsche Bank Biotech Boston Confab will be webcast and may be accessed at http://www.hgsi.com . (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HG...

Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments

- Treatment completed in Albuferon(R) Phase 3 trials; first Phase 3 data in December 2008 - - Enrollment completed in LymphoStat-B(R) Phase 3 trials; first Phase 3 data in mid-2009 - - HGS updates financial guidance - ROCKV...

RainDance Technologies Delivers RDT 1000, Sequence Enrichment Solution to The Genome Center at Washington University School of Medicine in St. Louis

LEXINGTON, Mass., Nov. 5 /PRNewswire/ -- RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced that it has shipped its new RDT 1000 instrument and Sequence Enrichment application to The Genome Center (GC) at t...

Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service

Pioneer in DNA Sequencing Deploys Clustered Storage to Help Redefine the Economics of Large-Scale Sequencing SEATTLE, Nov. 3 /PRNewswire-FirstCall/ -- Isilon(R) Systems (Nasdaq: ISLN), the leader in clustered storage, today announced that Complete Genomics, the world's first p...

Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results

ROCKVILLE, Md., Oct. 30 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended September 30, 2008. These results are expected to be disclosed on Thursday, November 6, 2...